A photo of Rebecca Marsh.

Clinical Director, Primary Immune Deficiency Program

Co-Director, Diagnostic Immunology Laboratories

Clinical Director, HLH Center of Excellence

Professor, UC Department of Pediatrics

513-636-3549

Board Certified

"Each patient and family is different, and I enjoy getting to know each person and helping them live their best life through optimal treatment of their immune deficiency."

My Biography & Research

Biography

I’ve always been fascinated by the immune system and also felt a calling to pediatrics. I enjoy working with people and developing long-term relationships with patients and families, so my career in primary immune deficiencies and hematopoietic cell transplantation is a perfect fit. My practice combines my love of immunology with caring for pediatric patients and working in a team-based setting.

As an immunologist and transplant physician, I treat patients with primary immune deficiencies and immune regulatory diseases, which are collectively called inborn errors of immunity. I’m the clinical director of the Primary Immune Deficiency Program and co-director of Diagnostic Immunology Laboratory.

Our practice provides a variety of treatments for patients, including allogeneic hematopoietic cell transplantation. Each patient and family is different, and I enjoy getting to know each person and helping them live their best life through optimal treatment of their immune deficiency.

We have a large group of specialists in the diagnosis and treatment of inborn errors of immunity. We also have the largest clinical laboratory specializing in primary immunodeficiency diagnostics. Our physician group consists of several experts in primary immunodeficiencies. Our physicians not only provide state-of-the-art treatment for patients, but they also lead the field with primary immune deficiency research and new treatment trials.

We have many nurse practitioners dedicated to caring for patients with inborn errors of immunity. Patients in our practice also work with a dedicated nurse coordinator who helps patients navigate their medical care. Our practice is special because we provide cutting-edge diagnostics and treatments for our patients and also maintain a supportive and caring team-based environment.

Through my research, I want to improve allogeneic hematopoietic cell transplantation for patients with primary immunodeficiencies. I’m also working to improve the treatment of patients with X-linked inhibitor of apoptosis (XIAP) deficiency and hemophagocytic lymphohistiocytosis (HLH).

In my free time, I like to play the piano, bake and spend time with my family.

Academic Affiliation

Professor, UC Department of Pediatrics

Clinical Divisions

Cancer and Blood Diseases, Immune Deficiencies and Histiocytosis, Bone Marrow Transplantation BMT, 22Q-VCFS, Hemophagocytic lymphohistiocytosisHLH, Rare Lung Diseases

Research Divisions

Bone Marrow Transplantation and Immune Deficiency, Cancer and Blood Diseases

My Locations

My Education

BS: University of Tennessee, Knoxville, TN, 1998.

MD: Rush Medical College, Chicago, IL, 2003.

Residency: Rush University Medical Center, Chicago, IL, 2006.

Fellowship: Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2008.

My Publications

Model-informed precision dosing for alemtuzumab in pediatric and young adult patients undergoing allogeneic hematopoietic cell transplantation. Dong, M; Emoto, C; Fukuda, T; Arnold, DE; Mehta, PA; Marsh, RA; Vinks, AA. British Journal of Clinical Pharmacology. 2021.

Evolution of Our Understanding of XIAP Deficiency. Mudde, AC A; Booth, C; Marsh, RA. Frontiers in Pediatrics. 2021; 9.

Test-dose pharmacokinetics guided melphalan dose adjustment in reduced intensity conditioning allogeneic transplant for non-malignant disorders. Chandra, S; Mizuno, K; Zhao, J; Davies, SM; Marsh, RA; Fukuda, T; Setchell, KD R; Vinks, AA; Mehta, PA. British Journal of Clinical Pharmacology. 2021.

Novel Treatment of Infant With COVID-19 With the Sialidase Fusion Protein, DAS181. Danziger-Isakov, L; Khalil, N; Divanovic, A; Frenck, R; Grimley, M; Iliopoulos, I; Marsh, R; Paulsen, G; Phillips, CL; Schulert, G; et al. Pediatric Infectious Disease Journal. 2021; 40:e234-e235.

Daratumumab for the management of autoimmune cytopenias in children and young adults: a case series. Khandelwal, P; Teusink-Cross, A; Kumar, AR; Bleesing, JJ; Mehta, PA; Jordan, MB; Chandra, S; Davies, SM; Marsh, RA. British Journal of Haematology. 2021.

A Toolkit and Framework for Optimal Laboratory Evaluation of Individuals with Suspected Primary Immunodeficiency. Knight, V; Heimall, JR; Chong, H; Nandiwada, SL; Chen, K; Lawrence, MG; Sadighi Akha, AA; Kumánovics, A; Jyonouchi, S; Ngo, SY; et al. Journal of Allergy and Clinical Immunology: In Practice. 2021.

Cutaneous T-cell lymphoma as a unique presenting malignancy in X-linked magnesium defect with EBV infection and neoplasia (XMEN) disease. Freeman, CM; Wright, BL; Bauer, CS; Rukasin, CR; Chiang, SC; Marsh, RA; Taylor, S; Jacobsen, J; Miller, HK; Badia, P. Clinical Immunology. 2021; 226.

T-cell activation profiles distinguish hemophagocytic lymphohistiocytosis and early sepsis. Marsh, RA; Zoref-Lorenz, A; Owsley, E; Chaturvedi, V; Nguyen, TC; Goldman, JR; Henry, MM; Greenberg, JN; Ladisch, S; Hermiston, ML; et al. Blood. 2021; 137:2337-2346.

The transcription factor Bcl11b promotes both canonical and adaptive NK cell differentiation. Holmes, TD; Pandey, RV; Helm, EY; Schlums, H; Han, H; Campbell, TM; Drashansky, TT; Chiang, S; Wu, CY; Tao, C; et al. Science Immunology. 2021; 6.

BCG-osis and Hematopoietic Cell Transplant for Primary Immunodeficiencies. Sabulski, A; Davies, SM; Paulsen, G; Marsh, R; Chandra, S. Journal of Clinical Immunology. 2021; 41:491-494.